Holen Sie sich die Stockscreener-App
1.4399
2.88%
0.0499
Schlusskurs vom Vortag:
$1.39
Offen:
$1.41
24-Stunden-Volumen:
180.49K
Relative Volume:
0.60
Marktkapitalisierung:
$43.36M
Einnahmen:
$1.05M
Nettoeinkommen (Verlust:
$-48.82M
KGV:
-0.7912
EPS:
-1.82
Netto-Cashflow:
$-47.49M
1W Leistung:
-13.33%
1M Leistung:
-19.66%
6M Leistung:
-83.86%
1J Leistung:
-66.82%
1-Tages-Spanne:
$1.365
$1.45
1-Wochen-Bereich:
$1.365
$1.6794
52-Wochen-Spanne:
$1.33
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Firmenname
Actinium Pharmaceuticals Inc
Sektor
Branche
Telefon
646-767-3870
Adresse
275 Madison Avenue, 7th Floor, New York, NY
Vergleichen Sie ATNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ATNM | 1.435 | 43.36M | 1.05M | -48.82M | -47.49M | -1.82 |
| VRTX | 449.74 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.25 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.30 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-02-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-11-05 | Eingeleitet | Alliance Global Partners | Buy |
| 2017-12-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-14 | Eingeleitet | Maxim Group | Buy |
| 2016-08-25 | Eingeleitet | ROTH Capital | Buy |
| 2016-02-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2014-10-01 | Eingeleitet | MLV & Co | Buy |
| 2014-07-22 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Actinium Pharmaceuticals Inc Aktie (ATNM) Neueste Nachrichten
Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks
Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK
Actinium Pharmaceuticals Reports $78.6M Cash Position, FDA Trial Clearances in Q3 | ATNM Stock News - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium: Q3 Earnings Snapshot - mySA
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World
Actinium Pharmaceuticals Inc (ATNM) Quarterly 10-Q Report - Quartz
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Actinium Pharmaceuticals Appoints June Almenoff to its Board of Directors - citybiz
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN
Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - ShareCafe
Before Buying Anterix Inc (NASDAQ: ATEX) Stock, Read This First - Stocks Register
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
ATNM: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Actinium Pharmaceuticals Inc (ATNM) requires closer examination - US Post News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Market Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on a High Note at 1.99 - The Dwinnex
Analysts Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) PT at $11.43 - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Rating Increased to Hold at StockNews.com - MarketBeat
Quarterly Snapshot: Quick and Current Ratios for Actinium Pharmaceuticals Inc (ATNM) - The Dwinnex
Finanzdaten der Actinium Pharmaceuticals Inc-Aktie (ATNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):